Yijun Xu

Yijun Xu

Auto-generated profile, based on publicly available information

Yijun Xu

Department of Thoracic Surgery, Tianjin Chest Hospital & Tianjin University Affiliated Chest Hospital, Tianjin, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
FCFeng Chen
Feng Chen
SGShaobo Gao
Shaobo Gao
WXWenchao Xia
Wenchao Xia
MWMeng Wang
Meng Wang
WZWei Zhang
Wei Zhang
YXYijun Xu
Yijun Xu
Background: As an increasing number of patients with both lung cancer and coronary artery disease (CAD) are being discovered, doctors face great challenges in treating this group. Off-pump coronary artery bypass grafting (CABG) combined with simultaneous radical surgery for lung cancer has become an option at some institutions. In this study, we aimed to explore postoperative complications, hospitalization duration and expenses, and surgical safety among patients who underwent simultaneous pulmonary resection and off-pump CABG, in order to provide a new treatment approach for lung cancer patients with coronary heart disease (CHD). Methods: This study collected 85 patients who underwent lung resection and off-pump CABG at Tianjin Chest Hospital from 2020 to 2023. According to different methods of lung surgery, it is divided into two groups: lobectomy combined with off-pump CABG and wedge resection combined with off-pump CABG. These two groups were compared with 78 patients who only received off-pump CABG in terms of hospitalization time and cost, perioperative safety, and surgical complications, in order to evaluate the feasibility of lung resection combined with off-pump CABG. Results: From the perspective of cardiac function, simultaneous pulmonary resection (lobectomy or wedge resection) and off-pump CABG did not affect postoperative cardiac function compared with off-pump CABG alone [left ventricle (LV): P=0.19; pulmonary artery systolic pressure (PASP): P=0.93; left ventricular ejection fraction (LVEF): P=0.89]. From the perspective of postoperative complications, the combined operation did not increase the incidence of respiratory-related complications (P=0.87) or cardiovascular-related complications (P=0.72) and secondary surgical events (P=0.19), but it did increase the incidence of surgery-related complications (such as chylothorax and air leakage), 15.4%:2.6%, which was manageable. In terms of perioperative safety, intraoperative blood loss during the combined operation was manageable (580 mL:450 mL) and did not significantly prolong the operation time (P>0.05). Conclusions: Off-pump CABG combined with pulmonary resection is safe during the perioperative period, and the incidence of postoperative complications is manageable, thus reducing overall hospitalization costs. However, combined surgery poses certain technical difficulties and should be performed at experienced institutions.

20 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FCFeng Chen
Feng Chen
XCXia Chen
Xia Chen
WZWenkang Zong
Wenkang Zong
YJYuhao Jing
Yuhao Jing
WXWenchao Xia
Wenchao Xia
YXYijun Xu
Yijun Xu
Background: Women with small-cell lung cancer (SCLC) often have longer overall survival (OS) without a corresponding progression-free survival (PFS) advantage. We investigated when this difference emerges.Methods: We conducted a two-cohort secondary analysis. SEER 17 data (2004–2023) assessed associations of sex with all-cause, SCLC-specific, and other-cause mortality. A hospital cohort was analyzed using an illness–death model of documented progression, death without previously documented progression, and death after progression. Multivariable Cox models, Aalen–Johansen state probabilities, restricted mean time in states, and sensitivity analyses were applied.Results: SEER included 107,474 patients and 99,299 deaths. Female sex was associated with lower all-cause mortality (hazard ratio [HR], 0.85; 95% CI, 0.84–0.86), SCLC-specific mortality (HR, 0.86; 95% CI, 0.85–0.87), and other-cause mortality (HR, 0.79; 95% CI, 0.76–0.82). The hospital cohort included 605 patients. Median OS was 17.5 months in women and 10.2 months in men, whereas median PFS was 7.9 and 7.6 months. Adjusted female-to-male HRs were 0.73 (95% CI, 0.55–0.95) for OS and 0.94 (95% CI, 0.75–1.17) for PFS. Female sex was not associated with progression (HR, 1.00; 95% CI, 0.75–1.33) or death without previously documented progression (HR, 0.91; 95% CI, 0.65–1.28), but was associated with lower mortality after progression (HR, 0.43; 95% CI, 0.27–0.68). Through 24 months, women accumulated 1.49 additional months alive after progression without additional progression-free time. The post-progression association persisted in sensitivity analyses and was not modified by recorded immune-checkpoint inhibitor exposure.Conclusions: The female OS advantage in SCLC appears to arise predominantly after documented progression. Prospective studies should examine post-progression treatment, supportive care, host resilience, and relapse biology.